Cutera, Inc., a medical device company, designs, develops, manufactures, markets, and services laser and other energy based aesthetics systems worldwide. The company offers enlighten platform, a laser system that is used for tattoo removal, as well as for the treatment of benign pigmented lesions; excel HR platform, a hair removal solution for various skin types; and truSculpt, a high-powered radio frequency platform designed for deep tissue heating. It also provides excel V, a vascular and benign pigmented lesion treatment platform; xeo platform, a multi-application platform on which a customer purchases hand piece applications for the removal of unwanted hair, treatment of vascular lesions, and skin rejuvenation by treating discoloration, fine lines, and laxity; Juliet, a laser system for vaginal health; and Secret RF, a fractional radio frequency microneedling device for skin rejuvenation. In addition, the company offers GenesisPlus system, a laser product for use in the temporary increase of clear nails in patients with onychomycosis, as well as for the treatment of fine wrinkles, diffuse redness, and rosacea; and CoolGlide, as well as myQ, a third-party sourced system for the Japanese market. Further, it provides pulsed light hand pieces for the treatment of discoloration, hair removal, and vascular treatments; Pearl and Pearl Fractional hand pieces; and post-warranty services through extended service contracts or direct billing, as well as offers Titan hand piece refills and marketing brochures through the Internet. The company markets and sells its products through direct sales force to plastic surgeons, dermatologists, gynecologists, family practitioners, primary care physicians, physicians performing aesthetic treatments in non-medical offices, and other qualified practitioners, as well as for physicians offering aesthetic treatments in non-medical offices. Cutera, Inc. was founded in 1998 and is headquartered in Brisbane, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Electromedical equipment
Sub-IndustryN/A
SectorComputer and Technology
Current SymbolNASDAQ:CUTR
Previous Symbol
CUSIPN/A
Phone415-657-5500
Debt
Debt-to-Equity RatioN/A
Current Ratio1.93
Quick Ratio1.24
Price-To-Earnings
Trailing P/E Ratio22.21
Forward P/E Ratio-58.97
P/E GrowthN/A
Sales & Book Value
Annual Sales$151.49 million
Price / Sales1.57
Cash Flow$0.8486 per share
Price / Cash Flow20.15
Book Value$4.68 per share
Price / Book3.65
Profitability
EPS (Most Recent Fiscal Year)$0.77
Net Income$29.99 million
Net Margins11.16%
Return on Equity-0.50%
Return on Assets-0.30%
Miscellaneous
Employees367
Outstanding Shares13,900,000
Market Cap$247.90 million
OptionableOptionable
Cutera (NASDAQ:CUTR) Frequently Asked Questions
What is Cutera's stock symbol?
Cutera trades on the NASDAQ under the ticker symbol "CUTR."
How will Cutera's stock buyback program work?
Cutera announced that its Board of Directors has initiated a stock buyback program on Tuesday, August 8th 2017, which authorizes the company to buyback $25,000,000.00 in shares, according to EventVestor. This buyback authorization authorizes the company to buy up to 6.8% of its stock through open market purchases. Stock buyback programs are generally an indication that the company's leadership believes its stock is undervalued.
How were Cutera's earnings last quarter?
Cutera, Inc. (NASDAQ:CUTR) announced its quarterly earnings data on Tuesday, November, 6th. The medical device company reported $0.11 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.03 by $0.08. The medical device company earned $40.60 million during the quarter, compared to analysts' expectations of $40.03 million. Cutera had a net margin of 11.16% and a negative return on equity of 0.50%. The business's quarterly revenue was up 6.4% on a year-over-year basis. During the same period in the prior year, the firm earned $0.42 earnings per share. View Cutera's Earnings History.
When is Cutera's next earnings date?
What guidance has Cutera issued on next quarter's earnings?
Cutera issued an update on its FY18 earnings guidance on Tuesday, November, 6th. The company provided EPS guidance of $0.40-0.50 for the period, compared to the Thomson Reuters consensus estimate of $0.31. The company issued revenue guidance of $165-170 million, compared to the consensus revenue estimate of $166.27 million.Cutera also updated its FY 2018 guidance to $0.40-0.50 EPS.
What price target have analysts set for CUTR?
4 equities research analysts have issued 12 month target prices for Cutera's stock. Their forecasts range from $24.94 to $50.00. On average, they expect Cutera's stock price to reach $34.6467 in the next year. This suggests a possible upside of 102.6% from the stock's current price. View Analyst Price Targets for Cutera.
What is the consensus analysts' recommendation for Cutera?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cutera in the last year. There are currently 1 sell rating, 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Cutera.
What are Wall Street analysts saying about Cutera stock?
Here are some recent quotes from research analysts about Cutera stock:
- 1. According to Zacks Investment Research, "Cutera Inc designs, develops, manufactures and markets the CoolGlide family of products for use in laser and other light-based aesthetic applications. The original CoolGlide CV provides permanent hair reduction on all skin types. The second generation CoolGlide Excel incorporated features that added the capability to treat a variety of vascular lesions, which include facial telangiectasia, spider and reticular leg veins. The CoolGlide Vantage added non-ablative skin therapy to the range of applications offered by the system. " (12/5/2018)
- 2. Gabelli analysts commented, "As a leading laser dermatology company, Cutera is an attractive long-term investment as management focuses on execution, growing sales and improving operating performance. Throughout 2017, Cutera revamped several members of its management team, including its CEO and CFO, along with several new hires to build out its sales and operational infrastructure in the US and internationally. Management is putting in place new processes to improve upon product development and scale up its organization for sustainable growth." (2/16/2018)
Has Cutera been receiving favorable news coverage?
News coverage about CUTR stock has been trending somewhat positive on Friday, according to InfoTrie Sentiment. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Cutera earned a coverage optimism score of 1.4 on InfoTrie's scale. They also gave news articles about the medical device company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future.
Who are some of Cutera's key competitors?
Some companies that are related to Cutera include Viewray (VRAY), BioLife Solutions (BLFS), Semler Scientific (SMLR), Rockwell Medical (RMTI), Electrocore (ECOR), Fonar (FONR), Zynex (ZYXI), Stereotaxis (STXS), Edap Tms (EDAP), Second Sight Medical Products (EYES), IRIDEX (IRIX), Viveve Medical (VIVE), Soleno Therapeutics (SLNO), Precision Optics (PEYE) and Digirad (DRAD).
Who are Cutera's key executives?
Cutera's management team includes the folowing people:
- Mr. James A. Reinstein, CEO, Pres & Director (Age 53)
- Ms. Sandra A. Gardiner, Exec. VP & CFO (Age 52)
- Mr. Larry E. Laber, Exec. VP of Sales - North America (Age 47)
- Mr. Ronald J. Santilli, Exec. Officer (Age 58)
- Mr. Jason Richey, Chief Operating Officer
Who are Cutera's major shareholders?
Cutera's stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (14.63%), Renaissance Technologies LLC (5.85%), Vanguard Group Inc (5.57%), Vanguard Group Inc. (5.57%), Gamco Investors INC. ET AL (4.77%) and Dimensional Fund Advisors LP (4.03%). Company insiders that own Cutera stock include David A Gollnick, David B Apfelberg, Gregory A Barrett, J Daniel Plants, James A Reinstein, Larry Laber, Miguel Pardos, Ronald J Santilli and Timothy J Oshea. View Institutional Ownership Trends for Cutera.
Which major investors are selling Cutera stock?
CUTR stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Point72 Asset Management L.P., Credit Suisse AG, Wells Fargo & Company MN, Strs Ohio, Vanguard Group Inc., Vanguard Group Inc and Panagora Asset Management Inc.. Company insiders that have sold Cutera company stock in the last year include David A Gollnick, David B Apfelberg, James A Reinstein and Larry Laber. View Insider Buying and Selling for Cutera.
Which major investors are buying Cutera stock?
CUTR stock was acquired by a variety of institutional investors in the last quarter, including Emerald Advisers Inc. PA, Emerald Mutual Fund Advisers Trust, BlackRock Inc., Gabelli Funds LLC, Gamco Investors INC. ET AL, SG Americas Securities LLC, Russell Investments Group Ltd. and Teton Advisors Inc.. Company insiders that have bought Cutera stock in the last two years include Gregory A Barrett and James A Reinstein. View Insider Buying and Selling for Cutera.
How do I buy shares of Cutera?
Shares of CUTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cutera's stock price today?
One share of CUTR stock can currently be purchased for approximately $17.10.
How big of a company is Cutera?
Cutera has a market capitalization of $247.90 million and generates $151.49 million in revenue each year. The medical device company earns $29.99 million in net income (profit) each year or $0.77 on an earnings per share basis. Cutera employs 367 workers across the globe.
What is Cutera's official website?
How can I contact Cutera?
Cutera's mailing address is 3240 BAYSHORE BOULEVARD, BRISBANE CA, 94005. The medical device company can be reached via phone at 415-657-5500 or via email at [email protected]
MarketBeat Community Rating for Cutera (NASDAQ CUTR)
MarketBeat's community ratings are surveys of what our community members think about Cutera and other stocks. Vote "Outperform" if you believe CUTR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CUTR will underperform the S&P 500 over the long term. You may vote once every thirty days.
